WHO meeting on preferred product characteristics for monoclonal antibodies for malaria prevention

Overview

On 3, 11 and 29 November 2021, the WHO Initiative for Vaccine Research and the Global Malaria Programme convened a Scientific Development Committee to review key issues in product development for monoclonal antibodies (mAbs) for malaria prevention. Experts reviewed and discussed the current landscape of malaria mAbs research and development, priority use case scenarios, and key product development considerations. The aim of the meeting was to develop preferred product characteristics (PPCs) for malaria mAbs.